Cargando…

4-1BB-Based CAR T Cells Effectively Reverse Exhaustion and Enhance the Anti-Tumor Immune Response through Autocrine PD-L1 scFv Antibody

Exhaustion of chimeric antigen receptor (CAR) T cells is one of the limitations for CAR T efficacy in solid tumors and for tumor recurrence after initial CAR T treatment. Tumor treatment with a combination of programmed cell death receptor-1 (PD-1)/programmed cell death ligand-1 (PD-L1) blockage and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cheng, Kang, Feng, Xiangming, Chai, Zhirong, Wang, Zhenzhen, Liu, Zheng, Yan, Zhanchao, Wang, Yanming, Zhang, Shoutao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9961031/ https://www.ncbi.nlm.nih.gov/pubmed/36835603 http://dx.doi.org/10.3390/ijms24044197

Ejemplares similares

Identification of Potent CD19 scFv for CAR T Cells through scFv Screening with NK/T-Cell Line
por: Kang, Chung Hyo, et al.
Publicado: (2020)

Augmenting the Effectiveness of CAR-T Cells by Enhanced Self-Delivery of PD-1-Neutralizing scFv
por: Ping, Yu, et al.
Publicado: (2020)

Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo
por: Rafiq, Sarwish, et al.
Publicado: (2018)

Inducible localized delivery of an anti-PD-1 scFv enhances anti-tumor activity of ROR1 CAR-T cells in TNBC
por: Harrasser, Micaela, et al.
Publicado: (2022)

Self-delivery of TIGIT-blocking scFv enhances CAR-T immunotherapy in solid tumors
por: Yang, Fan, et al.
Publicado: (2023)

scFv Antibody: Principles and Clinical Application
por: Ahmad, Zuhaida Asra, et al.
Publicado: (2012)

Target delivery of a PD-1-TREM2 scFv by CAR-T cells enhances anti-tumor efficacy in colorectal cancer
por: Chen, Jian, et al.
Publicado: (2023)

Nonspecificity in a nonimmune human scFv repertoire
por: Kelly, Ryan L., et al.
Publicado: (2017)

“Stapling” scFv for multispecific biotherapeutics of superior properties
por: Boucher, Lauren E., et al.
Publicado: (2023)

Isolation and characterization of human anti-CD20 single-chain variable fragment (scFv) from a Naive human scFv library
por: Shams, Nasir, et al.
Publicado: (2022)

Targeting scFv-Fc-scTRAIL fusion proteins to tumor cells
por: Hutt, Meike, et al.
Publicado: (2018)

Anti-Idiotype scFv Localizes an Autoepitope in the Globular Domain of C1q
por: Todorova, Nadezhda, et al.
Publicado: (2021)

The effects of N-terminal insertion into VSV-G of an scFv peptide
por: Dreja, Hanna, et al.
Publicado: (2006)

Empowering scFv with effector cell functions for improved anticancer therapeutics
por: Zhang, Hongtao
Publicado: (2013)

Integrating scFv into xMAP Assays for the Detection of Marine Toxins
por: Shriver-Lake, Lisa C., et al.
Publicado: (2016)

The Four-State Equilibrium Unfolding of a scFv Antibody Fragment
por: Pedroso, Idolka, et al.
Publicado: (2002)

Humanization and directed evolution of the selenium-containing scFv phage abzyme
por: Xu, Yan, et al.
Publicado: (2018)

Engineered Human Monoclonal scFv to Receptor Binding Domain of Ebolavirus
por: Densumite, Jaslan, et al.
Publicado: (2021)

Allogeneic gene-edited HIV-specific CAR-T cells secreting PD-1 blocking scFv enhance specific cytotoxic activity against HIV Env(+) cells invivo
por: Pan, Hanyu, et al.
Publicado: (2023)

Production and characterization of a recombinant anti-MUC1 scFv reactive with human carcinomas.
por: Denton, G., et al.
Publicado: (1997)

Recombinant production of the antibody fragment D1.3 scFv with different Bacillus strains
por: Lakowitz, Antonia, et al.
Publicado: (2017)

Improved scFv Anti-LOX-1 Binding Activity by Fusion with LOX-1-Binding Peptides
por: Hu, Wei, et al.
Publicado: (2017)

Production and characterisation of a recombinant scFv reactive with human gastrointestinal carcinomas
por: Kim, D-J, et al.
Publicado: (2002)

Generation and Characterization of an scFv Directed against Site II of Rabies Glycoprotein
por: Aavula, Shukra M., et al.
Publicado: (2011)

Production of scFv-Conjugated Affinity Silk Powder by Transgenic Silkworm Technology
por: Sato, Mitsuru, et al.
Publicado: (2012)

Early Detection of NSCLC with scFv Selected against IgM Autoantibody
por: Pedchenko, Tetyana, et al.
Publicado: (2013)

Development and identification of fully human scFv-Fcs against Staphylococcus aureus
por: Nian, Siji, et al.
Publicado: (2016)

Development of Human-Like scFv-Fc Neutralizing Botulinum Neurotoxin E
por: Miethe, Sebastian, et al.
Publicado: (2015)

Targeting HER2-breast tumors with scFv-decorated bimodal nanoprobes
por: Alric, Christophe, et al.
Publicado: (2018)

Generation of a Fully Human scFv that binds Tumor-Specific Glycoforms
por: Lu, Zhongpeng, et al.
Publicado: (2019)

Characterization and analysis of scFv-IgG bispecific antibody size variants
por: Cao, Mingyan, et al.
Publicado: (2018)

Development and in vitro characterization of a humanized scFv against fungal infections
por: Di Mambro, Tomas, et al.
Publicado: (2022)

Charachterization and functional analysis of scFv-based CARs to redirect T cells to IL13Rα2-positive glioma
por: Krenciute, Giedre, et al.
Publicado: (2015)

IL-13Rα2 humanized scFv-based CAR-T cells exhibit therapeutic activity against glioblastoma
por: Xu, Chang, et al.
Publicado: (2022)

Development of a Novel Anti-CD19 CAR Containing a Fully Human scFv and Three Costimulatory Domains
por: Wutti-in, Yupanun, et al.
Publicado: (2022)

Development of a human phage display-derived anti-PD-1 scFv antibody: an attractive tool for immune checkpoint therapy
por: Ghaderi, Sepideh Safaei, et al.
Publicado: (2022)

Anti-ROR1 scFv-EndoG as a Novel Anti-Cancer Therapeutic Drug
por: Bemani, Peyman, et al.
Publicado: (2018)

Enhancing the detection of Toxoplasma gondii via an anti-SAG1 scFv-alkaline phosphatase immunoconjugate
por: Hannachi, Emna, et al.
Publicado: (2019)

Relative Contribution of Framework and CDR Regions in Antibody Variable Domains to Multimerisation of Fv- and scFv-Containing Bispecific Antibodies
por: Bhatta, Pallavi, et al.
Publicado: (2018)

Development of a novel human phage display-derived anti-LAG3 scFv antibody targeting CD8(+) T lymphocyte exhaustion
por: Ascione, Alessandro, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_f5uvo2k8ovej5umjhmqruj0on2